Free shipping on all orders over $ 500

BMS-790052

Cat. No. M1843

All AbMole products are for research use only, cannot be used for human consumption.

BMS-790052 Structure
Synonym:

Daclatasvir; EBP 883

Size Price Availability Quantity
1mg USD 30 In stock
5mg USD 50 In stock
10mg USD 70 In stock
25mg USD 155 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BMS-790052 is a first-in-class, nonstructural protein 5A (NS5A) replication complex inhibitor with an EC50 of 9-50 pM. It is one of the most potent inhibitors of HCV replication reported so far. BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with EC50 of 7–13 pM. Residue 30 of NS5A is an important site for BMS-790052-mediated resistance in the hybrid replicons. BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups. BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic. At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1.

Chemical Information
Molecular Weight 738.88
Formula C40H50N8O6
CAS Number 1009119-64-5
Solubility (25°C) DMSO ≥40 mg/mL
Ethanol ≥40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Pelosi et al. Antimicrob Agents Chemother. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor Daclatasvir.

[2] Lim et al. J Biol Chem. Correlation between NS5A Dimerization and Hepatitis C Virus Replication.

[3] Kumthip et al. J Virol. Hepatitis C Virus NS5A Disrupts STAT1 Phosphorylation and Suppresses Type I Interferon Signaling.

[4] Jiang et al. J Chromatogr A. A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.

Related HCV Protease Products
Telaprevir

Telaprevir (VX-950) is a novel hepatitis C virus (HCV) NS3-4A protease inhibitor with IC50 of < 0.2 μM.

Elbasvir

Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) replication complex inhibitor, with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

Dasabuvir (ABT-333)

ABT-333 is a nonnucleoside NS5B polymerase inhibitor for the treatment of HCV infection.

Asunaprevir

Asunaprevir (BMS-650032) is a novel inhibitor of the hepatitis C virus enzyme serine protease NS3.

(R)-Nepicastat hydrochloride

(R)-Nepicastat hydrochloride, the R-enantiomer of Nepicastat hydrochloride, is a potent and selective inhibitor with IC50 of 25.1 nM and 18.3 nM for bovine and human dopamine-β-hydroxylase, with negligible affinity for twelve other enzymes and thirteen neurotransmitter receptors.

  Catalog
Abmole Inhibitor Catalog




Keywords: BMS-790052, Daclatasvir; EBP 883 supplier, HCV Protease, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.